Relay Therapeutics Inc (US:RLAY) — Company Overview, News & Financial Data
Relay Therapeutics leverages computational biology to discover new therapies targeting oncology and genetic disorders.
Relay Therapeutics Inc
Relay Therapeutics (NASDAQ:RLAY) is a company focused on leveraging advances in computational and structural biology to discover and develop new therapies. It operates at the forefront of precision medicine, with projects spanning from early discovery to clinical development, primarily targeting oncology and genetic disorders. Relay Therapeutics is passionate about deploying its proprietary technology to identify and develop molecules that can modulate protein functions in a dynamic manner, aiming to tackle diseases with high unmet medical needs. Its main objectives include advancing its current pipeline of potential treatments through clinical trials, expanding its research into new therapeutic areas, and continuously improving its drug discovery platform for better efficacy and patient outcomes. Relay Therapeutics is singularly listed on the NASDAQ under the ticker symbol RLAY, indicating its firm position in the biotechnology sector and commitment to innovation in drug discovery.
Snapshot
Operations
Products and/or services of Relay Therapeutics Inc
- Ripretinib, a tyrosine kinase inhibitor aimed at treating gastrointestinal stromal tumors.
- FGFR2 programs, focusing on advanced and metastatic cancers with FGFR2 fusions or mutations.
- PI3Ka inhibitor projects, targeting solid tumors with specific genetic mutations.
- SH2-containing inositol-5'-phosphatase (SHIP2) inhibition program for metabolic disorders.
- Protein motion inhibitors, a novel class aiming at undruggable targets across various cancers.
- Machine learning platforms for drug discovery, enhancing the speed and efficacy of identifying therapeutic candidates.
Relay Therapeutics Inc executive team
- Dr. Sanjiv K. Patel M.A., M.B.A., M.D., MBBSCEO, President & Director
- Mr. Thomas CatinazzoChief Financial Officer
- Mr. Peter RahmerChief Corporate Development Officer
- Dr. Donald A. Bergstrom M.D., Ph.D.President of Research & Development
- Ms. Dorothee Kern Ph.D.Founder
- Dr. David Elliot Shaw Ph.D.Founder
- Dr. Matthew P. Jacobson Ph.D.Founder
- Mr. Jim Watters Ph.D.Chief Scientific Officer
- Ms. Soo-Yeun LimSenior VP & General Counsel
- Dr. Mahesh Padval Ph.D.Chief Pharmaceutical Development Officer